S4646 polymorphism in XXXX gene is associated with the efficacy of hormone therapy in early @entity0 .

@entity1 @entity5066 @entity0 @entity73159 @entity4819 @entity11414 @entity5282
PURPOSE: The aim was to verify the potential association between @entity4819 genetic polymorphisms and clinical outcome of hormone therapy in @entity5282 (HR)-positive early @entity0 . METHODS: Genotyping for @entity4819 @entity73159 ( @entity11414 ) polymorphism was performed on 287 @entity1 with @entity0 . Associations were evaluated between @entity4819 @entity73159 genotypes and disease-free survival (DFS). RESULTS: Totally, @entity1 with the minor allele ( @entity5066 or AC) had an improved DFS when compared with those carrying the homozygous common allele (CC) ( @entity5066 or AC vs. CC: 62.7 months versus 55.6 months; Hazard ratio (HR), 0.745; 95% CI, 0.562-0.988; P = 0.04). The difference was further demonstrated by multivariate analyses (HR, 0.681; 95% CI, 0.506-0.917; P = 0.011). In premenopausal @entity1 , @entity5066 genotype was associated with a prolonged DFS ( @entity5066 versus CC or AC: 98.2 months versus 56.2 months; HR, 0.425; 95% CI, 0.198-0.914; P = 0.024). In addition, @entity1 with the A allele had an improved DFS when compared with those carrying the homozygous C allele ( @entity5066 or AC vs. CC: 62.7 months versus 55.6 months; HR, 0.709; 95% CI, 0.516-0.975; P = 0.033). These findings were further confirmed by the Cox regression model (HR, 0.336, 0.670; 95% CI, 0.160-0.836, 0.479-0.938; P = 0.017, 0.019). In postmenopausal @entity1 , @entity73159 genotypes were significantly associated with DFS ( @entity5066 versus AC versus CC: 32.7 months versus not reached versus 56.3 months; P = 0.011). @entity1 carrying @entity5066 variant had a poorer DFS than those with CC or AC genotypes (32.7 months versus 70.6 months; HR, 3.613; 95% CI, 1.380-9.457; P = 0.005). Furthermore, being adjusted by the @entity1 features in multivariate analyses, @entity5066 genotype remained an independent prognostic factor for DFS (HR, 3.614; 95% CI, 1.308-9.991; P = 0.013). CONCLUSIONS: The homozygous minor allele ( @entity5066 ) of @entity4819 @entity73159 is significantly associated with improved clinical outcome of hormone therapy in premenopausal @entity0 @entity1 , but with a worse impact on postmenopausal @entity1 . The findings are novel, if confirmed, genotyping for @entity4819 @entity73159 polymorphism may provide predictive information for better selection of endocrine treatment.
